现在红遍天下的光遗传学,大家(包括我)都认为是Stanford的Deisseroth创造的。但是昨天我不小心看到了一篇新闻文章,才惊讶的发现其实最早做出来的,有可能是Wayne State University的潘卓华。虽然他的投稿时间和Deisseroth的类似,但是因为他是一个没有什么名气的学者,而且他的文章包装得不对,所以他的文章被百般耽误,最后比Deisseroth的晚了一年才发表。
在2004年底潘就做出了和Deisseroth几乎一样的文章,除了用的细胞略微不同:他做的神经细胞是从视网膜分离的,而Deisseroth 做的神经细胞是从大脑分离的。然后他把文章陆续投向Nature, Nature Neuroscience,Journal of Neuroscience,却统统遭到了拒稿。然后大半年之后,也就是2005年8月份,Deisseroth 的文章发表在NatureNeuroscience上。潘得知之后,心都凉了。
有意思的是潘卓华发现自己的文章被人scoop之后写信问 Nature Neuroscience为什么两篇几乎一模一样的文章,他们接受了Deisseroth 的文章而不接受他的文章。对方回应说,虽然两篇文章非常相似,但是Deisseroth 的文章是作为一个技术文章来推销的,而潘的文章是作为恢复视觉的研究文章来写的。所以对方觉得他的文章"toonarrow", "too focused".
潘的文章最后发表在Neuron 上。他的文章比Deisseroth的更为完整,因为Deisseroth的只用了细胞,而他是直接用了老鼠来证明。但是这一切都晚了,因为他的文章最后比Deisseroth的晚了整整一年,大部分人看了都直接以为他的文章是跟风的,没有新意的一个“你做了细胞,我就做做老鼠看看”那种工作。于是Deisseroth成为了光遗传之父,而潘卓华什么都不是,他的实验室勉强维持着一个R01的水平
He may have invented one of neuroscience’s biggest advances. But you’ve never heard of him Zhuo-Hua Pan in his lab at Wayne State University in Detroit.
The next revolution in medicine just might come from a new lab technique that makes neurons sensitive to light. The technique, called optogenetics, is one of the biggest breakthroughs in neuroscience in decades. It has the potential to cure blindness, treat Parkinson’s disease, and relieve chronic pain. Moreover, it’s become widely used to probe the workings of animals’ brains in the lab, leading to breakthroughs in scientists’ understanding of things like sleep, addiction, and sensation.
So it’s not surprising that the two Americans hailed as inventors of optogenetics are rock stars in the science world. Karl Deisseroth at Stanford University and Ed Boyden at the Massachusetts Institute of Technology have collected tens of millions in grants and won millions in prize money in recent years. They’ve stocked their labs with the best equipment and the brightest minds. They’ve been lauded in the media and celebrated at conferences around the world. They’re considered all but certain to win a Nobel Prize.
There’s only one problem with this story:
It just may be that Zhuo-Hua Pan invented optogenetics first.
Even many neuroscientists have never heard of Pan.
Pan, 60, is a vision scientist at Wayne State University in Detroit who began his research career in his home country of China. He moved to the United States in the 1980s to pursue his PhD and never left. He wears wire-rimmed glasses over a broad nose framed by smile-lines in his cheeks. His colleagues describe him as a pure scientist: modest, dedicated, careful.
Pan was driven by a desire to cure blindness. In the early 2000s, he imagined that putting a light-sensitive protein into the eye could restore vision in the blind — compensating for the death of rods and cones by making other cells light-sensitive.
That was the germ of the idea of optogenetics — taking a protein that converts light into electrical activity and putting it into neurons. That way, scientists could shine light and stimulate the neurons remotely, allowing them to manipulate brain circuits. Others had experimented with trying to make neurons light-sensitive before, but those strategies hadn’t caught on because they lacked the right light-sensitive protein.
That all changed with the first molecular description of channelrhodopsin, published in 2003.
Channelrhodopsin, a protein made by green algae, responds to light by pumping ions into cells, which helps the algae search out sunlight.
That “was one of the most exciting things in my life,” Pan said. “I thought, wow! This is the molecule we are looking for. This is the light sensor we are looking for.”
By February 2004, he was trying channelrhodopsin out in ganglion cells — the neurons in our eyes that connect directly to the brain — that he had cultured in a dish. They became electrically active in response to light. Over the moon with excitement, Pan applied for a grant from the National Institutes of Health. The NIH awarded him $300,000, with the comment that his research was “quite an unprecedented, highly innovative proposal, bordering on the unknown.”
A side view of a blind mouse’s retina containing channelrhodopsin. The round structures at the bottom are the cell bodies of the neurons.
A close-up of the mouse retina showing neurons with channelrhodopsin and green fluorescent protein.
Pan didn’t know it at the time but he was racing against research groups across the United States and around the world to put channelrhodopsin into neurons.
Deisseroth and Boyden were working at Stanford, where Deisseroth was finishing a postdoc and Boyden was finishing graduate school. At least two other groups were in the game as well, led by Stefan Herlitze and Lynn Landmesser, who were at Case Western Reserve University at the time, and Hiromu Yawo at Tohoku University in Japan.
And they were by no means the only scientists experimenting with ways to control neurons with light. By 2004, Gero Miesenbock and Richard Kramer had already published articles using other, more complicated molecules for that purpose. But channelrhodopsin was the tool that was about to revolutionize the field.
The Stanford group had been toying with the idea of controlling neurons with light for quite some time. They had also noticed the paper about the discovery of channelrhodopsin. Deisseroth got in touch with the paper’s author, Georg Nagel, in March 2004 and asked if Nagel would collaborate, sharing the channelrhodopsin DNA so Boyden could try it out in neurons. In August 2004, Boyden shined light on a brain neuron in a dish and recorded electrical activity from the channelrhodopsin.
Pan had done the same thing with retina neurons six months earlier. But then he got scooped.
‘We didn’t feel very lucky’
Boyden, who is now a professor at MIT, was surprised when told by STAT that Pan ran the experiment first.
“Wow. Interesting. I didn’t know that,” Boyden said.
“It’s funny to think about how science regards when something is proven,” he added, noting that scientists build on each others’ work, sometimes working together while at other times working in parallel, scrambling onto one another’s shoulders. “There’s both intentional and unintentional teamwork,” he said.
The Stanford press office said Deisseroth was unavailable. In response to questions provided by STAT, spokesman Bruce Goldman wrote that Pan’s study was “a far cry from the use of optogenetics … to open up a new world of precision neuroscience. That’s the potential revealed in Dr. Deisseroth’s widely cited 2005 publication.”
Pan said he might have mentioned the timing of his experiment to Boyden once several years ago, but, Pan said, “I didn’t want to take too much time to talk about this because people feel uncomfortable.”
That sentiment is in keeping with Pan’s wider approach — diligent, reserved, outside the limelight. Wayne State is a small university not known for its scientific research. Pan had gone to a state school for his PhD, then done mostly obscure research for decades. These things may have contributed to what happened next, when he tried to get his invention out into the world: It wasn’t seen as the big advance it was.
A model of a human eye in Pan’s lab.
Pan spent the summer of 2004 figuring out how to get the channelrhodopsinprotein into a living eye. He settled on the idea of using a virus, whichcould infect cells in the eye and sneak the channelrhodopsin DNA inside. Hiscolleague, Alexander Dizhoor, a professor at Salus University, engineeredthe channelrhodopsin DNA to add the gene for a proteinthat fluoresced greenunder blue light, so they could track where the channelrhodopsin ended up.
In July 2004, Pan dosed his first rat with the virus. About five weeks later, he looked at the retinas to see if it had worked. What he saw was a sea ofgreen — thousands of ganglion cells had the green protein coupled tochannelrhodopsin in their membranes. And when he stuck an electrode in oneof those cells and turned on a lamp,thecell responded with a flurry ofelectrical activity. The channelrhodopsin was working. It was just a firststep, but it was a revolutionary step — indicating that Pan’s method mayjust be able to restore sight to the blind.
“Everything turned out beautifully,” Pan said.
So Pan and Dizhoor wrote a paper about their work and submitted it to Natureon November 25, 2004, according to the submission letter Pan shared withSTAT. The editors at Nature suggested they send it on to a more specializedjournal called Nature Neuroscience, which rejected it. Early the next year,Pan sent the paper to the Journal of Neuroscience, where it was reviewed butthen again rejected.
Disheartened, Pan set to work revising his paper, and in May 2005 traveledto Fort Lauderdale, Fla. for the Association for Research in Vision andOpthamologyconference, where he described his work using channelrhodopsin inneurons.That single lecture, lasting just 15 minutes, would come to be hisclearest stake along the timeline of invention.
It was what came next that would make that stake matter. A few months later,in August of 2005, Nature Neuroscience published a paper about usingchannelrhodopsin to make neurons sensitive to light. The paper was by EdwardBoyden and Karl Deisseroth.
Pan heard the news from a colleague who emailed him the paper. “I feltterrible. I felt terrible,” Pan said, pausing. “We didn’t feel very lucky.”
Met with a shrug
Deisseroth and Boyden’s paper was slightly different than Pan’s. Theysimply demonstrated that they could use channelrhodopsin to control neurons’ activity in a dish; Pan had waited to publish until he could make it workin a live animal. And Deisseroth and Boyden had shown incredibly precisetime control, by turning the light on for just a millisecond. But theirtechnical feat was essentially the same: They had used channelrhodopsin tosuccessfully make neurons in a dish respond to illumination.
The Stanford paper took a little while to take off, but take off it did. Thework jump-started both Deisseroth’s and Boyden’s careers, landing thembig money grants and talented students for their labs — Deisseroth atStanford and Boyden at MIT. The New York Times started writing aboutDeisseroth’s breakthroughs with optogenetics in 2007, and the citations ofthe research paper took off exponentially.
By the time Pan finally managed to publish his paper, in Neuron in April2006, it was mostly met with a shrug. Richard Kramer, a neuroscientist at UCBerkeley who was also studying vision, remembers, “It wasn’t thatcreative, it was just ‘Oh look, you can put channelrhodopsin in neuronsfrom the brain, you can also put it in neurons from the retina.’ Was itimpressive? No.”
Those handful of months seem to have made all the difference.
Culture dishes growing bacteria and dissection tools used in Pan’s lab.
Why didn’t Pan’s paper get published first? He may never know the answer.After Boyden’s paper came out, Pan wrote to the editor at NatureNeuroscience asking how they could have rejected his paper but publishedBoyden’s.
In her response, the editor replied that while the papers were similar,Boyden et al. presented theirs as a new technology rather than as ascientific finding. Pan’s paper, it seemed, was too narrow, only focusingon using channelrhodopsin to restore vision, while Boyden’s paper took thebroad view of thinking of channelrhodopsin as a tool for neuroscience ingeneral.
The reviews that other researchers submitted to the Journal of Neuroscienceshed some more light on what people thought of Pan’s paper. One reviewerliked it and had some minor suggestions for improvement. The other, in asingle long paragraph, said the research was “ambitious” and “verypreliminary” and concluded that “there is too little here to entice mostneuroscientists.”
In hindsight, Pan’s coauthor Dizhoor can’t help but laugh while readingthat. Reviewers would ultimately greenlight an expanded version of Pan’spaper, in 2006, with minimal revisions.
But that hasn’t elevated Pan to the optogenetics pantheon. In terms ofpublication, he was quite late to the party, with three different groupspublishing papers about channelrhodopsin before he did. He didn’t share intwo big prizes that recently went to Deisseroth and Boyden, the Brain Prizein 2013 (1 million euros split between six inventors of optogenetics) andthe Breakthrough Prize in 2015 ($3 million each to Boyden and Deisseroth).
Since 2005, Deisseroth has been awarded over $18 million in NIH grants forhis work on optogenetics, and Boyden has received more than $10 million.Both have other major projects that bring in additional funding to theirlabs each year. Boyden is a prolific speaker who’s given multiple TED talks; Deisseroth was the subject of an in-depth profile in the New Yorker in2015.
Pan, on the other hand, has cumulatively received just over $3 million overthe past 10 years and holds one NIH grant — the bare minimum to keep aresearch program going. Most of the accolades for his work have come fromWayne State University. According to his website, he’s been invited to givea couple of talks — most recently at a technology show in Russia.
Pan in his lab at Wayne State University, where he continues to work onchannelrhodopsin.
Rules of the invention game
The whole saga raises the question of what it means to invent something inscience. It’s a question that has plagued scientists in recent years —including the ongoing CRISPR patent fight — as research becomes ever moreglobal and the spoils of biotechnology and medical discoveries become evermore valuable.
The answer, it turns out, shifts depending on context.
Fellow academics often consider the first scientists to publish a paper on atechnique the discoverers or inventors of that technique.
But that metric can be problematic, as Pan’s experience shows. In a recentessay in the journal eLife, Ronald Vale and Anthony Hyman, two biologists,laid out the problem. They point out that “the delay between the submissionof a paper and its publication can range from a few weeks to more than twoyears,” adding that journals “slow down and create inequities in howknowledge is transferred from the scientist to the worldwide scientificcommunity.”
And reviewers can be biased toward familiar names or prestigiousinstitutions.Blinded review, in which the author’s name is redacted, hasbeen suggested as a way to minimize that effect, but many scientists areskeptical that it would work, since research is often discussed ahead oftime at conferences.
Vale and Hyman advocate, instead, for scientists to post drafts of theirwork on “preprint servers” such as bioRxiv before they submit it tojournals. If such a server had been widely used by neuroscientists in 2004,Pan could have posted his rejected findings there, staking his claim.
But whether that would mean he would be on the short list for the NobelPrize is unclear. Kramer thinks that even if Pan had published on bioRxiv,he’d be shut out because he wasn’t the first to publish a peer-reviewedpaper on the technique. That’s what will matter if and when the inventorsof optogenetics win the Nobel.
The legal system doesn’t play by quite the same rules. According to anAmerican Bar Association representative specializing in patent law, to proveprecedence for a patent in the early 2000s, most of the time you needed toshow both “when someone had actually conceived of the invention — that’ssort of in your mind the lightbulb going off, ‘Aha! I have it!’ — andwhen the invention was reduced to practice — that means you’ve actuallydone it and you’ve proven that your idea can work.”
By those standards, a discovery happens at the time of its demonstration inthe lab, even before it’s been posted on a preprint server.
Then there’s the court of public opinion. Scientists are increasinglypublic personalities, running Twitter accounts and appearing on late-nighttalk shows.
“The quality rising to the top is a little more influenced by non-scientific things than it used to be,” said Richard Masland, an emeritusprofessor at Harvard Medical School, who also holds patents on gene therapyfor blindness.
Being at Wayne State University might have meant that Pan didn’t have theresources to get a high-profile paperpublished. There’s the actual costsof doing high quality of research, but in addition, senior researchers attop universities usually mentor junior professors, reading their work andhelping them take it to the next level.
Pan agrees that fact may have put him at a disadvantage compared withscientists at prestigious institutions like MIT or Stanford. “Of course, Icannot prove that with evidence,” he said. And Pan’s modesty and non-native language abilities may have kept him from promoting himself as wellas Boyden and Deisseroth did.
“He’s just not as public a speaker and presenter as other people in thefield. And this is an important part of the whole game of being able to getout there and sell yourself,” Kramer, the UC Berkeley vision researcher,said.
That publicity can be self-reinforcing. Landmesser, the Case Westernprofessor who worked on channelrhodopsin in the beginning, said, “I thinkthere’s always a tendency [that] whoever gets there first gets morepublicity, let’s put it that way.”
A university PR video can spawn a national news article, which spurs someoneto think of your name in nominations for a nice cash prize, which leads tosome TV appearances. The word “inventor” gets used at some point andbefore you know it you’re Google’s automatic answer to the question “Whoinvented optogenetics?”
A chalkboard and glassware drying rack in Pan’s lab. He has usedchannelrhodopsin to help blind mice see.
Ultimately, both Pan and the team of Boyden and Deisseroth won patents fortheir discoveries.
Pan’s May 2005 lecture threatened to derail the Boyden-Deisseroth patentfor a while — the US patent office rejected it multiple times because Pan’s abstract was published more than a year before they got around to filing.
Eventually, Deisseroth and Boyden signed a document stating that they hadinvented this method of using channelrhodopsin privately in the lab beforePan’s conference abstract was published. The relevant patent was issued in
March 2016, almost 10 years after they filed.
Now, Deisseroth is a cofounder and scientific advisor at CircuitTherapeutics, a company developing a wide range of therapies based onoptogenetics, presumably using Deisseroth’s patented inventions. (CircuitTherapeutics declined to comment on specifics of their intellectual propertylicenses.)
Pan won a patent as well, to use channelrhodopsin to restore vision in theeye. His patent was licensed by RetroSense, which won an award from theAngel Capital Association in 2015. Retrosense — whose CEO in passing toldSTAT about Pan’s role in the invention of optogenetics — began clinicaltrials this year to put the algae proteins in blind people using genetherapy. It’s the first application of optogenetics in humans and the firsttime a non-human gene is being used in a gene therapy trial.
Right now, there are blind people in Texas walking around with algae DNA andproteins in their eyes. And that was what Pan was in it for all along. “One thing I still feel glad about is that even right now our clinical studyis still ahead of anyone,” Pan said.
But given that there are no gene therapies approved for clinical use in theUnited States, the road to successfully using optogenetics in humans willlikely be a long one. Yang Dan, a professor of neuroscience at UC Berkeleywho uses optogenetics to study sleep, isn’t betting on optogenetics curesbeing in the clinic any time soon. “I believe that these safety checks willtake a long, long time,” she said.
As for the invention itself, some scientists say Pan may not have had thebig, award-worthy vision that Deisseroth and Boyden had. Stefan Herlitze,one of the others who was scooped for the first publication aboutchannelrhodopsin in neurons, said, “Of course I have to say, Deisseroth andBoyden, they really developed the field further.”
Boyden echoed this. “Karl and I were very interested in the generalquestion of how to control cell types in the brain,” he said. “In recentyears, we worked to push these molecules to their logical limits.”
So maybe it doesn’t matter who invented optogenetics, just who hasstretched science’s boundaries the furthest.
Asked whether he deserves the recognition that Boyden and Deisseroth haveenjoyed, Pan declined to answer. He later told STAT that Deisseroth “alsodid a very excellent job, no doubt. But he’s also very lucky because if our paper was ahead of him, the story would be different. We would have gottenmore credit.”
That is about as much as Pan is willing to say about the way his cards fell.Today he’s still in Detroit. He’s been working on new versions ofchannelrhodopsin that could be used to cure blindness. “My lab is a verysmall lab,” Pan said, “We’re mainly interested in trying to restorevision.”
评论 (0)